

■ Time Table
Day 2, July 19 (Fri)

7月2日現在

		7	8	9	10	11	12	13	14	15	16	17	18	19		
Kyoto International Conference Center	Main Hall	1F		O2-1 Gastrointestinal Cancer1 E 8:20-9:35	O2-2 Hepatobiliary/Pancreatic Cancer E 9:35-10:50		MeS-15 Understanding Response and Resistance Mechanisms to IO therapy N 11:40-12:30		General Assembly 13:40-14:30	Award Lecture	PS2 Presidential Session2 E 16:00-18:00			ES-15 Personalized Immunotherapy for Advanced NSCLC: Understanding Sensitivity and Resistance N 18:30-19:20		
	Annex 1	1F	EL17 Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC) 8:50-9:20	EL18 Primary Liver Cancer 8:50-9:20	EL19 The Progress and Management of the Chemotherapy in Biliary and Pancreatic Cancer 9:20-9:50	EL20 Small Cell Lung Cancer 9:50-10:20	EL21 Advance of Treatment for Lung Cancer 10:20-10:50	EL22 Recent Development of Treatment Strategy for Early Breast Cancer 10:50-11:20		MeS-16 Treatment strategies for HR positive HER2 negative metastatic breast cancer N 11:40-12:30	SY8 Circulating Biomarkers E 15:10-17:10	EL23 Ovarian Cancer 17:10-17:40	EL24 Treatment for Patients with Endometrial Cancer and Cervical Cancer 17:40-18:10	ES-16 Genome guided medicine in the clinical practice N 18:30-19:20		
	Annex2	1F		SY9 Changes in Investigator-initiated Clinical Trials after Implementation of the Clinical Research Act 8:20-10:20		O2-3 Clinical Trial Facilitation Program 10:20-11:35		MeS-17 Has your 1L treatment of non-small cell lung cancer changed in 2019? N 11:40-12:30			EL25 Systemic therapy for metastatic breast cancer 15:20-15:50	EL26 Systemic Therapy for Genitourinary Cancers 15:50-16:20	EL27 Recent Topics on Primary Bone and Soft Tissue Tumors and Metastatic Bore Tumors 16:20-16:50	EL28 Recent Advances in Therapeutics for Malignant Lymphoma 16:50-17:20	MO2-1 Cross-sectional Program 1 (Cancer Genomic Testing) 17:20-18:10	ES-17 Do We Need Oral Care for Cancer Treatment?: Practice Tips for Oral Care 18:30-19:20
	Room A	2F		O2-4 Multidisciplinary Team Program 8:20-9:35	PD2 The Safety Management of Chemotherapy - Anticancer Drug Exposure, Prevention and Education 9:35-11:35		MeS-18 IO in stage II NSCLC: First year of clinical experience and expectations for the future N 11:40-12:30				WS2 Support for Working Cancer Survivors: Healthcare Providers' Role in Hospital Settings 15:10-17:10	MO2-2 Gastrointestinal Cancer7 E 17:10-18:00			ES-18 Opportunities for new value creation via integrated platform of clinical diets for cancer 18:30-19:20	
	Room B-1	2F	MoS-1 Optimal treatment of BRAF/MEK inhibitor combination therapy in the case of BRAF positive melanoma and NSCLC 7:20-8:10		MO2-3 Breast Cancer2 E 9:00-9:50	MO2-4 Breast Cancer3 E 9:50-10:40	MO2-5 Head and Neck Cancer1 E 10:40-11:30	MeS-19 Vascular promotion and normalization in the tumor microenvironment for drug delivery/The genomic landscape of breast cancer N 11:40-12:30			MO2-6 Head and Neck Cancer2 E 15:10-16:00	PS2 Presidential Session2(relay) 16:00-18:00			ES-19 Applications of targeted sequencing in hematology/oncology 18:30-19:20	
	Room D	1F	MoS-2 Systemic therapy for hepatocellular carcinoma ~past and future~ 7:20-8:10		SPS2 Basic Lecture on Cancer Genome Medicine 9:00-10:20	O2-5 Rare Cancer (Soft Tissue Sarcoma) 10:20-11:35		MeS-20 Bringing BRCA mutations come into breast cancer care N 11:40-12:30			SY10 Sequential Treatment Strategy after the Failure of First-line Tyrosine Kinase Inhibitor for Lung Cancer E 15:10-17:10	O2-6 Cross-sectional Program 17:10-18:25			ES-20 AE managements for treatments in Hodgkin Lymphoma 18:30-19:20	
	Room E	1F	MoS-3 Management of Tumor lysis syndrome 7:20-8:10		MO2-7 Palliative Care/Symptom Management1 9:00-9:50	MO2-8 Palliative Care/Symptom Management2 9:50-10:40	MO2-9 Palliative Care/Symptom Management3 10:40-11:30	MeS-21 Novel treatment for thyroid cancer, from the aspect of genetic alteration N 11:40-12:30			MO2-10 Translational Research2 15:40-16:30	MO2-11 Translational Research3 16:30-17:20	MO2-12 Translational Research4 17:20-18:10		ES-21 Frontline of SOS/VOD treatment 18:30-19:20	
	Sakura	1F	MoS-4 Present and Future of molecular targeted therapy in breast cancer 7:20-8:10		JSMO Membership Committee Promotion of Work Style Reform of Medical Staffs 8:30-9:30	PSY4 Promising Treatment of Tomorrow N 9:30-11:00		MeS-22 How I Treat Oncogene-Driven Advanced NSCLC N 11:40-12:30			PSY5 Utilization of Big Data in Cancer Care 15:40-17:40	EL29 The latest advances in precision therapy and immunotherapy for adult leukemia 17:40-18:10			ES-22 Treatment strategy for pancreatic cancer in elderly patients 18:30-19:20	
	Swan	1F	MoS-5 Management of Endocrine Dysfunction Following the Use of Immune Checkpoint Inhibitor: Experiences and Recommendation from an Endocrinologist 7:20-8:10		MO2-13 Lung Cancer/Thoracic Cancer2 (NSCLC/Others) E 9:00-9:50	MO2-14 Lung Cancer/Thoracic Cancer3 (Locally Advanced) E 9:50-10:40	MO2-15 Lung Cancer/Thoracic Cancer4 (NSCLC-EGFR-TKIs) E 10:40-11:30	MeS-23 How to change gastrointestinal neuroendocrine neoplasms treatment ~in light of the impact of WHO2019 classification~ N 11:40-12:30			MO2-16 Lung Cancer/Thoracic Cancer5 (NSCLC) E 15:40-16:30	MO2-17 Lung Cancer/Thoracic Cancer6 (NSCLC-Immune Checkpoint Inhibitors) E 16:30-17:20	MO2-18 Lung Cancer/Thoracic Cancer7 (NSCLC-Immune Checkpoint Inhibitors2) E 17:20-18:10		ES-23 Optimal Clinical Genomic Profiling to Guide Patient Selection for Targeted and Immune Therapies Using the MSK-IMPACT, MSK-Pancreas, and MSK-ACCIS assays 18:30-19:20	
	Grand Prince Hotel Kyoto	Royal Room	1F	MoS-6 Supportive Care on the treatment for cancer 7:20-8:10		JSMO Committee on Public Information and Negotiation Program Tobacco Control Session 9:00-10:00	PSY6 Accelerating Drug Development and Approval Utilizing a Platform Trial in Japan 10:00-11:30	MeS-24 What is the Optimal Treatment Strategy for ALK positive Lung Cancer? N 11:40-12:30			SY11 The Appropriate Selection of Anti-cancer Drugs According to Cost Effectiveness E 15:30-17:30				ES-24 Thinking beyond ADC: some new cancer drugs on the horizon 18:30-19:20	
Rose Room		B1F	MoS-7 Tumor Microenvironment and PD-1 blockade in Hodgkin Lymphoma 7:20-8:10		JS4 Joint Symposium 4 (JCA/JSCO/JSMO) Clinical Implementation in Cancer Genome Medicine 8:20-10:20	SY12 New Strategy of Peri-operative Therapy for Resectable Gastric Cancer E 10:30-11:30	MeS-25 Significance of late line chemotherapy in metastatic colorectal cancer N 11:40-12:30			MS3 Revisiting the PARP Inhibitors in New Era for Ovarian Cancer E 15:00-16:30	SY13 Molecular Abnormalities and Clinical Development of New Drugs for Thyroid Cancer E 16:30-17:35			ES-25 Present status and future prospect of immunotherapy for head and neck cancer 18:30-19:20		
Gold Room		B2F			AOJS Asia Oceania/JSMO Joint Symposium Joint Symposium of Asian Medical Oncology Societies ~ To Further Develop Relationship for Asian Patients ~ N 9:00-11:00		MeS-26 New treatment strategy for Microsatellite Instability-High (MSI-High) cancer N 11:40-12:30			PSY7 Genome Based Clinical Trials: What is Next Generation Clinical Trials? N 15:30-17:10				ES-26 Updated on Treatment and Diagnosis for Driver mutations in NSCLC 18:30-19:20		
Kyoto International Conference Center	Room C-1	1F					MeS-27 In combination with resectant chemotherapy for high-grade localized soft tissue sarcoma: What's Local Hyperthermia as Demonstrated in the Evidence? Including Their Risks and Benefits? N 11:40-12:30							ES-27 Precision Medicine in Gynecologic Cancers N 18:30-19:20		
	Room C-2	1F					MeS-28 Current status of chemotherapy for unresectable pancreatic cancer N 11:40-12:30							ES-28 Diagnosis and Treatment of Neuroendocrine Tumors 18:30-19:20		
	Room B-2	2F		DL7 Current and Future Directions for the Treatment of Advanced Thyroid Cancer E 8:40-9:30	DL8 Current approach to the treatment for the elderly myeloma patients E 9:40-10:30	DL9 Speeding Drug Development Through Neoadjuvant Therapy E 10:40-11:30	MeS-29 Management of oral mucositis in clinical practice ~ What can be done by medical dental cooperation ~ N 11:40-12:30			DL10 A Patient-centric Approach to Pancreatic Cancer Research: the Pancreatic Cancer Action Network Experience E 15:00-15:50	DL11 CLINICAL PROFILE AND TREATMENT OUTCOMES OF LYMPHOMA PATIENTS: A REAL WORLD EXPERIENCE E 16:20-17:10	DL12 Reference centers and precision medicine trials in sarcoma E 17:20-18:10		ES-29 What is the Best Practice in chemotherapy for mCRC? 18:30-19:20		
	Room 104 (Meet the Experts)	1F		ME7 Evolving Management Paradigm of Advanced NSCLC E 8:20-9:20	ME8 Novel Targeted Therapies in Gastric Cancer, Moving Beyond PD1 E 9:20-10:20	ME9 How to Implement Personalized Medicine E 10:20-11:20				ME10 Immuno-precision Medicine in Gastric Cancer: How to Select The Proper Patients? E 15:00-16:00	ME11 Understanding Response and Resistance Mechanisms to IO therapy E 16:20-17:20	ME12 Liquid Biopsy for NSCLC: From Research to Practice E 17:20-18:20				
	Room 510 (Patient Advocate Program)	5F		PAP 臨床試験とガイドライン 9:30-10:20	PAP 個別化医療とゲノム医療 10:30-11:20	PAP ラフセッション がん免疫療法~これまでと、これから~ 11:40-12:30			PAP がんの薬物療法 13:00-13:50	PAP 放射線治療 14:00-14:50	PAP PMDA(医薬品医療機器総合機構) 15:00-16:00 ~新しい医療が国民に届くまで/ 私たちができること~					
	Event Hall-New Hall (Poster Area)	1F		Putting up posters 8:20-9:20	Poster Display 9:20-12:40			Poster Session 12:40-13:35			Poster Display 13:35-18:20			Poster removal 18:20-19:20		

Explanatory Notes

- SPS =Special Presidential Session
- PS =Presidential Session
- AOJS =Asia Oceania/JSMO Joint Symposium
- JS =Joint Symposium
- PSY =Presidential Symposium
- SY =Symposium
- MS =Mini Symposium
- PD =Panel Discussion
- WS =Workshop
- EL =Educational Lecture
- DL =Distinguished Expert Lecture
- ME =Meet the Experts
- McS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral Abstract Session
- MO =Mini-Oral Abstract Session
- P =Poster
- N Simultaneous Interpretation (E&J)
- E English Session